Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176145 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL29473571 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL5156811 | 0.78 | TSHR (0.50) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL1176630 | 0.78 | TSHR (0.50) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL5852687 | 0.76 | TSHR (0.54) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL1119954 | 0.76 | TSHR (0.54) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL29434698 | 0.76 | TSHR (0.54) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL10300821 | 0.76 | TSHR (0.54) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL13241617 | 0.75 | SLC6A2 (0.42) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL14499061 | 0.75 | SLC6A2 (0.42) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854958-A | Preparation method of blue light prevention photochromic lens substrate | 江苏视科新材料股份有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-116854958-A | Preparation method of blue light prevention photochromic lens substrate | 江苏视科新材料股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-116731498-A | Blue light-proof photochromic resin lens | 江苏视科新材料股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-9359317-B2 | Small molecule inhibitors of HIV proteases | PURDUE RESEARCH FOUNDATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-20140135321-A1 | SMALL MOLECULE INHIBITORS OF HIV PROTEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-05-15 | — | — | US | disclosed |
| US-20110046199-A1 | SMALL MOLECULE INHIBITORS OF HIV PROTEASES | PURDUE RESEARCH FOUNDATION (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046199-A1 | SMALL MOLECULE INHIBITORS OF HIV PROTEASES | SERPINB1, PRSS1, TMPRSS15 | SLC6A4 4546/4885SLC6A2 4731/4885SLC6A3 4470/4885 |
| US-20140135321-A1 | SMALL MOLECULE INHIBITORS OF HIV PROTEASES | SERPINB1, PRSS1, TMPRSS15 | SLC6A4 4546/4885SLC6A2 4731/4885SLC6A3 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.